The examine, partly funded by the complement maker, discovered a mix of oral remedy with DHA and citicoline considerably improved visible capability and fee of development in sufferers with glaucoma after three months of remedy.
NI Award Judges praised the analysis for highlighting an space of well being that has not been broadly investigated. In addition they famous the strong methodology that includes a randomized management trial with a robust pattern, in addition to the spectacular final result.
“We’re so pleased to obtain this honor,” mentioned BrudyLab’s medical director Leia Garrotte, following the awards ceremony in Geneva on Might 15. “It was our first time at this contest, and the group was completely wonderful. Our workforce is thrilled with the chance to share this award and the great outcomes of the examine.”
Antioxidant properties
Glaucoma is a progressive optic neuropathy that impacts 57.5 million people around the world. It’s the second-leading reason behind blindness after cataracts. This blindness is normally irreversible.
The examine authors famous that many sufferers with glaucoma are really helpful to take nutraceuticals containing nutritional vitamins, citicoline or ginkgo biloba, amongst others, in medical apply.
Citicoline is an indispensable middleman within the synthesis of cell membrane phospholipids and a potential neuroprotectant or neuromodulator. In some international locations it’s used to facilitate restoration from stroke lesions or to deal with neurodegenerative ailments. In the meantime, DHA is an omega-3 polyunsaturated fatty acid with widely-demonstrated antioxidant properties.
Research particulars
The possible, randomized and single-blind examine aimed to guage the impact of citicoline, vitamin C and docosahexaenoic acid (DHA) in sufferers with glaucoma.
The researchers randomly assigned 73 sufferers with glaucoma into one among 4 teams and handled them for 3 months with vitamin C, DHA, citicoline or a mix of DHA and citicoline.
All sufferers had a month-to-month full ophthalmic examination to investigate totally different visible parameters over time. Researchers assessed and in contrast adjustments within the visible fields in every group.
The mixture of oral remedy with DHA and citicoline considerably improved visible capability and fee of development in sufferers with glaucoma after three months.
“Solely the mixture of oral remedy with our DHA (Tridocosahexanoina-AOX) together with citicoline considerably enhanced visible capability and decelerated illness development in glaucoma sufferers after three months’ intervention,” Garrotte mentioned.
The examine demonstrates that the mixture of DHA and citicoline can enhance visible operate in these sufferers, regardless of lack of imaginative and prescient being usually irreversible on this group.
BrudyLab maintains that the examine exhibits sufficient potential for the mixture to turn out to be a top-seller for glaucoma sufferers. There’s additionally room to discover the synergistic antioxidant neuromodulatory impact. The authors speculate that each compounds enhance one another to facilitate speedy turnover of cell membrane structural elements. It is a potential software associated to totally different neurological pathologies, similar to Alzheimer’s or Parkinson’s Illness.
“This mission proves that nutraceuticals have a robust potential to assist glaucoma sufferers,” Garrotte mentioned. “Science is the pillar of our enterprise in BrudyLab. We’re happy with our foremost aim, era of medical proof, with excessive requirements to spice up the vitamin business.”
Supply: Life
doi: 10.3390/life12101481
“The Impact of Oral Citicoline and Docosahexaenoic Acid on the Visible Subject of Sufferers with Glaucoma: A Randomized Trial.”Authors: Anton et al.
